

IN THE CLAIMS

Please substitute pending claims 1, 3, 8-9, 13-16, 19-20, 22-23, 26, 28, 45, 47, 51-53, 57-60, 63-64, 66-67, 70 and 72 with the corresponding amended claims, as shown below:

Cut Subt D

1. (Twice Amended) A method for the treatment, prophylaxis, or reduction of the risk of developing a menopause disorder in a mammal in need thereof, comprising administering to the mammal a menopause disorder effective amount of methyltestosterone in an oral dosage unit, and at least one pharmaceutically acceptable steroid selected from the group consisting of estradiol, testosterone, androstenedione, androstenediol, dehydroepiandrosterone, prenenolone, and dihydrotestosterone, and enantiomers, isomers, prodrugs or salts of the same in a non-oral dosage unit.

Cut Subt D

3. (Amended) The method of claim 1, wherein the methyltestosterone is administered in the form of a tablet, capsule, cachet, lozenge, dispensable powder, granule, solution, suspension, emulsion or liquid.

Cut Subt D

8. (Amended) The method of claim 7, wherein the testosterone is administered percutaneously.

Cut Subt D

9. (Amended) The method of claim 8, wherein the testosterone is administered in the form of a hydroalcoholic gel.

Cut Subt D

13. (Amended) The method of claim 10, wherein the thickener is polyacrylic acid.

14. (Amended) The method of claim 1, wherein the steroid is estradiol.

15. (Amended) The method of claim 14, wherein the estradiol is administered percutaneously.

Cut Subt D

16. (Amended) The method of claim 15, wherein the estradiol is administered in the form of a hydroalcoholic gel.

BEST AVAILABLE COPY

CS Subt D
19. (Amended) The method of claim 18, wherein the thickener is polyacrylic acid.

20. (Amended) The method of claim 1, wherein the methyltestosterone and the steroid are each provided as a separate component of a kit.

CS Subt D
22. (Amended) The method of claim 1, wherein the methyltestosterone and the steroid are administered in a sequential manner.

CS Subt D
23. (Amended) The method of claim 1, wherein the methyltestosterone and the steroid are administered in a substantially simultaneous manner.

CS Subt D
26. (Amended) The method of claim 1, wherein the methyltestosterone is administered in an amount of about 0.2 mg to about 50.0 mg, and the steroid comprises testosterone administered in an amount of about 0.1 g to about 100.0 g.

CS Subt D
28. (Amended) The method of claim 1, wherein the methyltestosterone is administered in an amount of about 0.2 mg to about 50.0 mg methyltestosterone, and the steroid comprises estradiol administered in an amount of about 0.1 g to about 100.0 g.

CS Subt D
45. (Twice Amended) A method for the treatment, prophylaxis, or reduction of the risk of developing a menopause disorder in a mammal in need thereof, comprising administering to the mammal in a combination therapy methyltestosterone in an oral dosage unit, and at least one pharmaceutically-acceptable steroid selected from the group consisting of estradiol, testosterone, androstenedione, androstanediol, dehydroepiandrosterone, prenenolone, and dihydrotestosterone, and enantiomers, isomers, prodrugs or salts in a non-oral dosage unit, wherein the amount of methyltestosterone and the steroid together make a menopause disorder effective amount.

CB
47. (Amended) The method of claim 45 wherein the methyltestosterone is administered in the form of a tablet, capsule, cachet, lozenge, dispensable powder, granule, solution, suspension, emulsion or liquid.

CB
51. (Amended) The method of claim 45, wherein the steroid is testosterone.

52. (Amended) The method of claim 51, wherein the testosterone is administered percutaneously.

53. (Amended) The method of claim 52, wherein the testosterone is administered in the form of a hydroalcoholic gel.

CB
57. (Amended) The method of claim 54, wherein the thickener is polyacrylic acid.

58. (Amended) The method of claim 45, wherein the steroid is estradiol.

59. (Amended) The method of claim 45, wherein the estradiol is administered percutaneously.

60. (Amended) The method of claim 59, wherein the estradiol is administered in the form of a hydroalcoholic gel.

CB
63. (Amended) The method of claim 62, wherein the thickener is polyacrylic acid.

64. (Amended) The method of claim 45, wherein the methyltestosterone and the steroid are each provided as a separate component of a kit.

CB
66. (Amended) The method of claim 45, wherein the methyltestosterone and the steroid are administered in a sequential manner.

67. (Amended) The method of claim 45, wherein the methyltestosterone and the steroid are administered in a substantially simultaneous manner.

BEST AVAILABLE COPY

C45
70. (Amended) The method of claim 45, wherein the methyltestosterone is administered in an amount of about 0.2 mg to about 50.0 mg, and the steroid comprises testosterone administered in an amount of about 0.1 g to about 100.0 g.

C46
72. (Amended) The method of claim 45, wherein the methyltestosterone is administered in an amount of about 0.2 mg to about 50.0 mg methyltestosterone, and the steroid comprises estradiol administered in an amount of about 0.1 g to about 100.0 g.

Please cancel Claims 2, 4-6, 46, and 48-50, without prejudice or disclaimer.

BEST AVAILABLE COPY